Disclosure Information

I hereby declare that I have had business or personal interests in the following industrial enterprises since 1 September 2016:

<table>
<thead>
<tr>
<th>Name of the enterprise / Nature of the interest</th>
</tr>
</thead>
</table>
Business Meeting
Digestive Diseases Working Group

29th ECP
Amsterdam 05.09.2017
Agenda

• DD WG
  – On the ESP portal
  – Current status
• ECP Amsterdam 2017
• Joint activities with other organizations
• ECP Bilbao 2018
• Other achievements and projects
• Any other business
Membership

• Since 2015, every member of the ESP had to apply for membership of WG(s).
• Application on the website, has to be approved by the WG chair.

<table>
<thead>
<tr>
<th>Year</th>
<th>Members</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>118</td>
<td>28</td>
</tr>
<tr>
<td>2015</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>2016</td>
<td>165</td>
<td>39</td>
</tr>
<tr>
<td>2017</td>
<td>195</td>
<td>47</td>
</tr>
</tbody>
</table>
ESP Amsterdam 2017

• Went jointly for the GI tract and liver-pancreas
• Proposals by the WG, approval by the scientific committee

• 8 Sessions
  – 5 symposia – short courses (1 ESP/Rodger Haggitt Society, 1 ESP/UEG, 1 Cytopathology WG/DDWG)
  – 1 slide seminar
  – 1 Business meeting
  – 1 Videomicroscopy (EAHP/DDWG)

• Oral free papers and posters
SY-12 Joint Symposium Digestive Diseases Pathology & UEG: Barrett's dysplasia management in 2017: Optimising pathology-endoscopy crosstalk

Jacques Bergman, Netherlands
Detecting early Barrett’s neoplasia: Do high-end endoscopic techniques really make a difference?

Michael Vieth, Germany
Pathology diagnosis of Barrett's initiation and progression: A controversy coming to an end

Rehan Haidry, United Kingdom
Accurate staging of Barrett's neoplasia with endoscopic resection

Matthew Stachler, USA
Genomic evolution of Barrett’s progression

Sybren Meijer, Netherlands
Risk stratification in Barrett's neoplasia through digital platforms and molecular profiles
03 September 2017 | 08:30 - 12:00 | Elicium 1

SY-02 Joint Symposium Digestive Diseases Pathology / Rodger Haggitt Society: Update in pathology of GI tumours

Fátima Carneiro, Portugal
Update in diffuse gastric cancer

Sanjay Kakar, USA
Update on changes in the AJCC of GI cancers

Alessandro Lugli, Switzerland
Tumour budding in GI carcinomas

Graham Rondell, USA
PD-L1 and immunotherapy of GI cancers: What you need to know

Christophe Rosty, Australia
Serrated polyposis of the GI tract
ESP Amsterdam 2017

• Went jointly for the GI tract and liver-pancreas
• Proposals by the WG, approval by the scientific committee

• 8 Sessions
  – 5 symposia – short courses (1 ESP/Rodger Haggitt Society, 1 ESP/UEG, 1 Cytopathology WG/DDWG)
  – 1 slide seminar
  – 1 Business meeting
  – 1 Videomicroscopy (EAHP/DDWG)

• Oral free papers and posters
202 (236) abstracts GIT
81 (75) abstracts Liver/Pancreas

Scored
by WG reviewers

Scientific Committee
ESP

28 (10%) Oral free paper presentations
183 (65%) physical posters
141 GIT
42 Liver/Pancreas

49 (17%) E-Posters
29 GIT
20 Liver/Pancreas

283/1838 (15.4%)
311/2002 (15.5%)

+ designation of the George Tiniakos award recipient
ECP Bilbao 2018

- GIT and Liver/Pancreas together
- Proposal by Chairman and Secretary, taking into account your suggestions, and including common sessions (Rodger Haggitt Society, Hans Popper Society, UEG, ECCO, Paediatric pathology WG)
- Will include common sessions GIT – Liver/Pancreas
- Decision by the Scientific Committee (to come)
Other achievements and projects (1)

• ESP Advanced Training Centres & Giordano Fellowship
  – 2 centres on GI, 2 on liver

• ECCO (European CanCer Organisation): contribution to the text “ECCO ESSENTIAL REQUIREMENTS FOR QUALITY CANCER CARE OF COLORECTAL CANCER » (Crit Rev Oncol Hematol 2017; 110:81-93.)

Other achievements and projects (2)

- ICCR/ESP datasets:
  - Intrahepatic and Perihilar Cholangiocarcinoma and Hepatocellular carcinoma. Approval by C Sempoux and J-F Fléjou
  - ESP Taskforce (Iris Nagtegaal): WG welcomes the initiative

- Proposal of a COST project on Tumour/Stroma Ratio (W Mesker): the WG has accepted to participate, you should be solicited

- Task force ESP-UEMS progress test (F Bosman): The WGs have to give their feedback on test items (October 2017)
And to conclude

• Any questions?
  – Now
  – Later
    • jean-francois.flejou@aphp.fr
    • christine.sempoux@chuv.ch